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Non-melanoma skin cancer is common and offers 
unrivaled opportunities to relate genetic changes to 
clinical and biologic behavior. Recent technical ad-
vances in molecular biology render genetic analysis of 
even the smallest skin cancers possible. In this review I 
will discuss the role of p53 gene in skin carcinogenesis, 
N on-melanoma skin cancer (NMSC) is a molecular oncologist's dream-or at least it should be. In many Caucasian populations NMSC is the com-monest human malignancy [1-3]. Precursor le-sions such as actinic keratoses and Bowen's disease 
are even more common; tumors such as squamous cell carcinoma 
(SeC) and basal cell carcinoma (.~CC), although both, bein~ kera~­
inocyte derived, show marked dIfferences 111 chrucal and bIOlog1c 
behavior [1,2]; inherited syndromes such as the nevoid basal cell 
carcinoma syndrome (NBCCS), characterized by multiple BCCs, 
and the Ferguson-Smith syndrome, characterized by multiple self-
healing SCCs, exist. And importantly not only is there a high rate of 
non-progression from ill situ lesions to invasive tumors, but also a 
high rate of spontaneous regression [4]. Furthermore, the clinician's 
natural experiments throw down the gauntlet to the would-be mo-
lecular scientist, demanding explanations. Why do patients receiv-
ing immunosuppressive therapy following organ transplant show 
an increased tumor incidence It]? What is the mechanism of psora-
len plus ultraviolet A (PUVA)-induced tumors-via mutation or 
through UVR-induced cutaneous immunosuppression [1)? How 
and why do retinoids exert their effects? The most puzzling aspect 
of NMSC genetics is that it has been so neglected - at least until 
recently. 
Tumorigenesis is characterized by an accumulation of genetic 
abnormalities [5,6]. The control of DNA fidelity is central to the 
pathogenesis of cancer. Various studies show that most epithelial 
cancers harbor multiple genetic abnormalities, and furthermore that 
there is a strong relationship between the accumulation of these 
abnormalities and the clinico-pathologic behavior of the tumor 
[5,6]. For many of the tumor types studied.' pro~ression from benig.n 
hyperproliferation through dysplasia to lllvaSlOn and. metastas1S ~s 
accompanied by an increase in the frequency of genetic abnormah-
ties [5,7] . Some of these changes, if not all, are thought to be causally 
related to the development of cancer. The importance of multiple 
genetic hits in this multi-stage process is easily o~erlooke~ . In .sev-
eral experimental systems, one or even two genetic alteratIOns 1S all 
that is required to alter a cultured cell's phenotype to that of a cancer 
cell [8]. Although experimentally useful, these model systems or 
assays miss out a key stage in the development of cancer, namely, 
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that normal cells appear to be able to inhibit the clonal growth of 
cells harboring only one or two genetic alterations [8]. Multiple 
abnormalities may be required to escape from this inhibitory COI1-
trol, allowing clonal expansion to occur. 
ONCOGENES AND TUMOR-SUPPRESSOR GENES 
Genes involved in the development of cancer are usefully classed as 
either oncogenes or tumor-suppressor genes. Recently a third class 
of genes, thought to be involved in DNA mismatch repair, have 
been implicated in the etiology of hereditary non-polyposis colo-
rectal cancer and other tumors [9]. Their role in NMSC is not at 
present clear, and they will not be discussed further. 
All cancers involve the disruption of the normal constraints on 
cell proliferation or cell death, and the classification of cancer-re-
lated genes into oncogenes or tumor-suppressor genes reflects this 
defining characteristic of the cancer cell: genes involved in cancer 
either help stimulate cell proliferation (or inhibit cell death) 
whereas their normal products have the opposite effect. In these 
simplistic terms there are two genetic routes to cancer. Firstly, on-
cogenes, genes whose presence in the cell due to, for instance, exog-
enous viral DNA, or an activating mutation of a normal cellular 
~ene, leads to the development of a cancer by stimulating prolifera-
tion. Charactensttcally these mutations have a dominant effect-
only one of the cell's two copies is required to undergo mutation. 
Oncogenes are frequently the result of activating mutations of a 
cell's normal genes, so called proto-oncogenes. Over 50 such proto-
oncogenes have been identified, although only a dozen or so have 
been implicated in the development of spontaneously occurring 
human cancers . The others have, in Weinberg's words, been identi-
fied through the "artifice of recombinant DNA" [8]. The second 
road to cancer is to make an inhibitory gene inactive. This type of 
mutation has a recessive effect-both cellular copies must be 
inactivated - and the inactivated gene is called a tumor-suppressor 
gene. 
The oncogene most often implicated in the etiology of non-mel-
anoma skin cancer is ms, which demonstrates many of the arche-
typal features of this class of genes. Ras genes are found ubiquitously 
in eukaryotes and are part of a gene superfamily including rho, rai, 
rapt, and rap2. Ras proteins are associated with the inner aspect of 
the cell membrane and are thought to playa critical role in signal-
transduction pathways involved in growth and differentiation 
[10,11]. Mutations at various codons lead to a protein that is penna-
nently activated, with the result that in many cell types a switch to 
cellular hyperproliferation occurs [10]. Ras oncogenes were among 
the first human oncogenes identified, and earlier work suggested 
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that mutation of ras, especially Harvey ras and Kirsten ras, was 
common in NMSC (reviewed in [1 2,13]). More recent work has, 
however, yielded different results, showing a low frequency of mu-
tation in non-melanoma skin cancer [14,15,16] . The reasons for 
these experimental differences are not clear. Technical artifact may 
be important, as some studies fa iled to carry out confirmatory se-
quencing of putative mutants screened using dot blots. More inter-
esting, however, is the possibility that there may be genuine differ-
ences in the molecular epidemiology of ras mutations in different 
populations and disease groups. For instance, various groups of pa-
tients with xeroderma pigmentosa [17 ,18], as well as different Cau-
casian populations [12,13], show very different frequencies of ras 
mutations; it is possible that these different genetic footprints reflect 
different patterns of causal influences. 
If the 1980s were labeled the decade of oncogenes, the 1990s 
belong to tumor-suppressor genes. In many epithelial neoplasms, 
inactivation of tumor-suppressor genes appears more common than 
activation of oncogenes [5,8] . T his may reflect (arguing teleologi-
cally) the need for tissues characterized by a high rate of prolifera-
tion, such as colon or skin, to develop cellular mechanisms or "cel-
lular brakes" to defend against uncontrolled hyperproliferation and 
cancer. A cell would therefore only undergo malignant change 
when all these defensive checks have been removed. Alternatively, 
and more mundanely, the frequency of identification of abnormali-
ties of tumor-suppressor genes may reflect the fact that it is techni-
cally easier to identify putative tumor-suppressor genes than to 
identify new oncogenes. The concept of tumor-suppressor genes 
and tumor-suppressing activity dates back to the work of Harris and 
colleagues in the late sixties (reviewed in [19]). In a series of elegant 
experiments involving fusing tumorigenic and non-tumorigenic 
cells, Harris showed that the resulting hybrids shared the phenotype 
of the normal, rather than the tumor cell. Over the next few decades 
technical advances involving single chromosome transfer and trans-
fection of indiv~dual genes allowed the suppressing activity origi-
nally identified in Harris's experiments to be localized to particular 
chromosomes and then to particular genes [1 9]. However, the im-
portance of tumor-suppressor genes in the development of human 
cancer was championed and given a wider currency by the work of 
Knudson [20]. Based on observations on the epidemiology of reti-
noblastoma, Knudson hypothesized that if tumor-suppressor genes 
were recessive at the cellular level and patients suffering from in-
herited cancer syndromes such as retinoblastoma inherited only one 
abnormal allele, a further somatic mutation in the remaining allele 
would lead to cancer (or at least be a rate-limiting step in the devel-
opment of cancer). Individuals inheriting an abnormal allele are 
predisposed to cancer because every cell already harbors one abnor-
mal allele. The importance of this hypothesis for cancer genetics is 
difficult to overestimate. Firstly, it linked germ-like mutations and 
somatic mutations: familial cancer and sporadic cancer [21]. Patients 
who inherit one abnormal allele are more likely to develop cancer 
because only one further genetic hit on the normal allele is required; 
alternatively, in the vast majority of individuals who do not inl1erit 
any abnormality, cancer will be more rare because inactivation of 
both the alleles will be required - but the same genes are involved 
in familial and sporadic tumors. T he hypothesis also makes explicit 
that whereas at the cellular level the abnormality may be recessive 
(as Harris's experiment suggested), the inherited syndrome (as in 
retinoblastoma) will be (autosomal) dominant. At least some of the 
reason for the explosion of interest in tumor-suppressor genes has 
been that the somatic inactivation of one allele is often due to the 
loss of a part of the relevant chromosome. This loss of an allele or 
loss of heterozygosity can be easily detected using restriction frag-
ment length polymorphisms (RFLP) on Southern blots, or by using 
microsatellite polymer chain reaction analysis. Based on Knudson's 
work, many of the genes implicated in the rare familial syndromes 
have now been shown to be important in the much more common 
sporadic tumors. To date two such genes have attracted interest in 
non-melanoma skin cancer: p53 and a putative tumor-suppressor 
gene on chromosome 9 responsible for the NBCCS. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
p53 TUMOR-SUPPRESSOR AND ONCOGENE? 
The gene for p53 codes for a 53-kd phosphoprotein that was origi-
nally identified on the basis of its binding to the large T antigen of 
SV 40 (reviewed in [22 - 26]). Abnormalities of this gene are the 
most fre9uent abnormali ty yet identified in human cancer including 
NMSC l25,27]. Amidst a wealth of data documenting the role of 
this gene in human cancer, two experiments stand out, one from the 
clinic, and one from the laboratory. Firstly, many patients with the 
Li-Fraumeni multiple cancer syndrome have a germ-line mutation 
of p53 [21] . These patients show a high risk of developing a variety 
on cancers including breast, lymphoid, and melanoma (but not ap-
parently NMSC). Secondly, transgenic mice in which both alleles 
of the gene have been inactivated ("knockouts") develop normally 
ill utero but show a greatly increased instance of tumors post-natally; 
mice that are hemizygous for p53 also show an increased tumor 
incidence but not as great as in the null mice [28]. Although some 
features of p53 are typical of what one might expect of a classical 
tumor suppressor gene, the position is not as straightforward as with 
retinoblastoma [21,24] . Loss of the normal tumor-suppressing role 
of p53 gene is clearly important, but it is also evident that mutations 
of p53 can be associated with a gain of function as well as a loss of 
function ]29,30]. p53 can be inactivated in several ways including 
mutation, loss of the part of chromosome 17p harboring the gene, 
or binding of the products of certain oncogenic tumor viruses to the 
wild-type protein (including the large T antigen ofSV 40, which led 
to the original identification of p53) [31]. Binding of the human 
papillomavirus 16 E6 protein to p53, for instance, results in a loss of 
function of the wild-type protein, and, at least ill vitro, along with 
other transforming genes for the human papillomavirus, appears to 
contribute to the ability of human papilloma virus to transform cells 
[31] . 
What of p53 and NMSC? p53 mutations occur commonly in 
both BCCs and SCCs, although the absolute rates of mutation vary 
between 10% and 90% in the various studies [14,32,33]. Mutation 
appears to precede invasion in the development of SCC, being 
present in up to 40% of Bowen's disease cases [34] . The pattern of 
mutations, with C ---> T and CC ---> TT base changes predominat-
ing, reflects the role of UVR-induced DNA damage in the patho-
genesis of these tumors, and at the same time has acted as a molecu-
lar footprint confirming the role of UVR as a relevant mutagen for 
NMSC [33]. As was mentioned above, p53 appears to have proper-
ties of both an oncogene and a tumor-suppressor gene [24]. For 
instance, in BCCs, loss of the remaining wild-type allele following 
mutation of one allele is uncommon, although in some tumors both 
alleles may harbor a mutation. In SCCs, however, as in many other 
human neoplasms, the mutant allele is frequently accompanied by 
loss of the remaining allele (loss of heterozygosity). 
Although the p53 gene is widely expressed, the level of protein is 
such that under standard immunocytochemical conditions protein 
expression is difficult to detect in normal tissues including skin. 
Conversely, however, many mutations of p53 lead to a protein that 
is abnormally stable, rendering the detection of the mutant protein 
in tissue sections possible. This apparent abil ity to distinguish be-
tween cells with mutant p53 and wild-type p531ed to great enthusi-
asm for using immunocytochemistry as a screening method or 
proxy for p53 mutation [35 - 38]. Although the attractions are 
obvious - immunocytochemistry is quicker and cheaper than 
DNA sequencing- it is now clear that the original optimism was 
not justified [1 4,32]. Firstly, the attempt to distinguish between 
mutant and wild-type p53 using immunocytochemistry always 
took advantage of a relative difference in signal intensity . p53 im-
munostaining, however, can be detected in normal skin, albeit at 
low levels, and by increasing the sensitivity of the detection systems 
or by using microwave-enhanced antigen retrieval, one can readily 
detect wild-type p53 in normal skin. Secondly , and perhaps more 
importantly, there are clear instances of a dissociation between the 
intensity of immunostaining and the presence or absence of muta-
tion. For instance, one of the functions of p53 is thou ght to be 
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mediating growth arrest following DNA damage. If skin is exposed 
to erythemal or even sub-erythemal doses of UVR, wild-type pro-
tein is rapidly induced as a result of stabilization of the protein 
product [39 - 41 ]. Interestingly, the intensity and the pattern of this 
accumulation is dependent upon the wavelength ofUVR used [40]. 
Secondly, the presence of mutant p53 in itself may not be sufficient 
for immunostaining. Some truncated proteins due to nonsense mu-
tations will of course not possess the correct epitopes, but, more 
importantly, cells from patients with the Li-Fraumeni syndrome, 
despite the presence of a p53 mutation, are immunonegative. It also 
appears that some tumors harboring missense mutations are also 
immunonegative [32]: the context of the tumor cell may influence 
the accumulation of p53 protein. Conversely, immunostaining may 
be seen without detectable mutation [32]. Barnes et at described a 
cancer family where strong p53 immunostaining was seen in skin, 
but no p53 coding region mutation could be identified [42] . There-
fore, although in many instances p53 immunostaining is associated 
with malignancy, positive immunostaining cannot be taken to 
imply p53 mutation, nor can the absence of immunostaining ex-
clude mutation. Although DNA damage (such as occurs secondary 
to UVR exposure) resu lts in the accumulation of wild-type p53 
protein, other signals and signal-transduction pathways may be rel-
evant. For instance, in human skin various stimuli including certain 
irritants not known to have a primary DNA damaging potential 
result in a modest elevation of p53 [41]. 
NEVOID BASAL CELL CARCINOMA SYNDROME 
AND CHROMOSOME 9 
Many genes involved in inherited cancer syndromes are also impor-
tant in the more common sporadic tumors. Because for many 
tumor-suppressor genes mutation of one allele is often accompanied 
by loss of the remaining allele, examination of the patterns of loss of 
heterozygosity in sporadic tumors may give clues to the location of 
as yet unidentified tumor-suppressor genes important both in spo-
radic and familial syndromes. Bale's group took advantage of this 
strategy to map the gene responsible for the NBCCS [43]. They 
screened sporadic BCCs for evidence of loss of heterozygosity 
(LOH) and found LOH to be a frequent event on chromosome 9q. 
Having obtained this clue to the position of the putative gene, they 
then proceeded to use classical linkage analysis in a number of 
kindreds with NBCCS to show that the disorder mapped to the 
same area commonly deleted on chromosome 9. Intriguingly, the 
Ferguson-Smith syndrome, characterized by multiple self-healing 
SCCs also maps to 9q [44], and not only sporadic BCCs but also 
sporadic SCCs show LOH on chromosome 9 [45]. Whether the 
same gene is implicated in both the NBCCS and the Ferguson-
Smith syndrome as well as in sporadic BCCs and SCCs is not clear. 
However, recent work based on minimal deletion mapping of spo-
radic BCCs and SCCs suggests that the putative tumor-suppressor 
genes for these different tumor types reside on different parts of 
chromosome 9 [46]. These results are in keeping with results on 
other human cancers that suggest that there may be more than one 
tumor-suppressor gene on chromosome 9. 
It is salutary to note that many of the advances in our understand-
ing of the genetics of NMSC owe more to an increase in technical 
facility than to any conceptual breakthrough or change in our abil-
ity to devise more critical experiments. The dominant paradigm 
underpinning much of the present work in human NMSC owes 
much to earlier work in other cancer systems, particularly the work 
of Fearon and Vogelstein on human colorectal cancer [5]. However, 
until recently one of the rate-limiting steps in studying NMSC has 
been the technical difficulties in working with small lesions. Actinic 
keratoses, for instance, often provide insufficient DNA for South-
ern hybridization. The advent of polymerase chain reaction micro-
satellite analysis and the ability to carry out direct sequencing 
from formalin-fixed histologic sections, however, means that it 
will only be a matter of time before the roles, if any, of other 
putative tumor-suppressor genes and oncogenes in the pathogenesis 
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ofNMSC are elucidated. For instance, we are only just begilllling to 
explain in genetic terms the differences between BCCs and SCCs 
[47]. What are the important genetic differences between actinic 
keratoses and SCCs [48]? Can we explain why a keratoacanthoma 
behaves difFerently from a SCC? What in genetic terms is the pre-
cursor of a BCC? What is the normal function of p53 in skin? Is it, 
in David Lane's words, a "guardian of the genome" in the face of 
continual UVR-induced DNA damage, or does it carry out a num-
ber of other physiologic functions [49]? Is its role in apoptosis in 
other cell types relevant to normal keratinocyte differentiation? 
The accessibility of skin, the ability to perform limited experiments 
in vivo, and the sheer richness of the c1inicaI presentation of NMSC 
means that the answer to many of these questions cannot be long in 
coming; for these reasons and others, understanding the genetics of 
NMSC may also provide new insights into other human cancers. 
Work itl my laboratory is JII/lded by the Medical Research COJwci! a/ld rhe North oj 
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ANNOUNCEMENT 
A symposium sponsored by the Deutsche Forschungsgemeinschaft and the Alexander-von-
Humboldt-Foundation, "Molecular Mechanisms in Dermal-Epidermal Interactions," will be 
held in Klosterlrsee/Germany (approximately 120 km west of Munich), March 10-13, 1995. 
It is being organized by E. Christophers, Kiel; T. Krieg, Cologne; and D. Roop, Houston. 
The aim of this symposium is to discuss the role of cell-cell and cell-matrix connection for 
cellular differentiation, embryonic development, wound healing, and inborn as well as acquired 
diseases of the skin. The meeting will include plenary lectures, poster sessions, and workshops. 
Participants will be limited to 80 to allow a detailed and profound discussion. 
Application forms for participation should be sent to prof. T. Krieg, Department of Derma-
tology, 50924 Kbln, FRG. 
